MST2 Antibody

What is MST2 and what are its primary functions in cellular signaling?

MST2 (mammalian sterile twenty-like 2, also known as STK3 and Krs-1) is a 58 kDa serine/threonine kinase belonging to the GCKII group of the STE20 subfamily. It is a critical regulatory protein in the evolutionarily conserved Hippo signaling pathway, which controls tissue growth and organ size by regulating cell proliferation, apoptosis, and stem cell self-renewal .

In humans, MST2 is 491 amino acids in length with a defined domain structure including:

• One kinase domain (amino acids 27-278)

• Two nuclear export signals (NESs, amino acids 361-371 and 438-447)

• Coiled-coil domains (amino acids 287-328 and 442-475)

• One nuclear localization signal (NLS, amino acids 473-487)

MST2 exhibits remarkable functional duality - it can promote either pro-apoptotic or proliferative responses depending on the cellular context and stimulus type . In the Hippo pathway, MST1/2 kinases and the SAV1 scaffold protein form a complex that phosphorylates and activates LATS1/2 kinases, which subsequently phosphorylate YAP and TAZ, promoting their cytoplasmic sequestration and inhibition .

What are the most common applications for MST2 antibodies in research?

MST2 antibodies are versatile tools employed across multiple experimental techniques:

These applications allow researchers to detect endogenous MST2 protein expression, activation status, and interactions with other proteins in various experimental contexts .

What should researchers consider when selecting an MST2 antibody?

When selecting an MST2 antibody, researchers should carefully evaluate:

• Species reactivity: Most commercial MST2 antibodies show cross-reactivity with Human, Mouse, Rat, and sometimes Monkey and Bovine samples .

• Specificity and sensitivity: Many antibodies detect endogenous levels of MST2 protein with high specificity . Verify the antibody can recognize the target at physiological expression levels.

• Application compatibility: Ensure the antibody is validated for your specific application. Not all antibodies perform equally across different techniques .

• Storage conditions: Most MST2 antibodies require storage at +4°C after thawing, with long-term storage at -20°C to -70°C. Avoid repeated freeze/thaw cycles to maintain antibody performance .

• Antibody format: Available as polyclonal or monoclonal variants, with various conjugations depending on experimental needs .

How can researchers effectively monitor MST2 activation status?

MST2 activation can be monitored through several complementary approaches:

• Phosphorylation detection: The gold standard for assessing MST2 activation is detecting phosphorylation at Thr-180, which indicates activating autophosphorylation. This can be accomplished using phospho-specific antibodies in Western blot analysis .

• Caspase-mediated cleavage: MST2 activation often involves caspase-3-mediated cleavage between Asp322 and Ser323, generating a 36-kDa fragment. Antibodies that recognize both full-length and cleaved forms can be used to monitor this process .

• Subcellular localization: Upon activation, MST2 typically translocates from the cytoplasm to the nucleus. Immunofluorescence or subcellular fractionation followed by Western blotting can track this translocation .

• In vitro kinase assays: Immunoprecipitated MST2 can be assessed for kinase activity using exogenous substrates such as myelin basic protein (MBP). This approach directly measures enzymatic activity rather than surrogate markers .

• Downstream substrate phosphorylation: Monitoring phosphorylation of direct MST2 substrates, particularly LATS1/2, provides functional confirmation of MST2 activity .

What methodological considerations are critical when studying MST2-protein interactions?

When investigating MST2 interactions with binding partners such as BRAF or RASSF1A:

• Co-immunoprecipitation optimization:

  • For detecting MST2-BRAF interactions, immunoprecipitate either endogenous BRAF or MST2 using specific antibodies followed by immunoblotting for the partner protein .

  • Consider crosslinking approaches for transient interactions.

  • Use appropriate controls, including IgG controls and input samples.

• Cell treatment conditions:

  • BRAF inhibitor treatment (e.g., PLX4032/vemurafenib at 1-3 μM) disrupts MST2-BRAF interaction, which should be considered when designing timecourse experiments .

  • Different BRAF inhibitors (Type I ½ vs Type II) affect the MST2-BRAF interaction to varying degrees .

• Protein expression levels:

  • Overexpressed proteins may form non-physiological interactions.

  • Consider using tagged versions (FLAG-MST2, Myc-LATS1) to facilitate detection while being mindful of tag interference .

• Detection sensitivity:

  • For endogenous interactions, enhanced chemiluminescence or more sensitive detection methods may be required .

How can researchers effectively use MST2 antibodies in immunohistochemistry applications?

For optimal immunohistochemical detection of MST2:

• Sample preparation:

  • Use immersion-fixed paraffin-embedded sections (FFPE).

  • Documented successful applications in human kidney, placenta, and colon carcinoma tissues .

• Protocol optimization:

  • Antigen retrieval methods significantly impact staining quality.

  • A typical dilution of 1:250 has been validated for some antibodies .

  • Chromogenic detection using DAB (3,3'-diaminobenzidine) provides good visualization of MST2 expression .

• Controls and validation:

  • Include positive control tissues with known MST2 expression (e.g., placenta).

  • Consider counterstaining with hematoxylin for tissue architecture context .

  • Validate staining patterns with alternative detection methods or antibodies.

• Interpretation considerations:

  • MST2 may show both cytoplasmic and nuclear localization depending on activation state.

  • Compare expression patterns with other Hippo pathway components for contextual understanding .

How does MST2 contribute to the dual regulation of cell proliferation and apoptosis?

MST2 exhibits context-dependent dual functionality that requires careful experimental design to elucidate:

In apoptotic signaling:

• MST2 acts as a pro-apoptotic kinase activated by various stimuli including doxorubicin.

• Activation involves homo-oligomerization, autophosphorylation on Thr-180, and caspase-3-mediated cleavage .

• Knockdown of MST2 impairs doxorubicin-induced apoptosis, reducing markers like cleaved PARP and cleaved caspase-3 .

• MST2 is a substrate of caspase-3 that can accelerate caspase-3 activation in a positive feedback loop .

In proliferative signaling:

• MST2 supports Raf-1→ERK signaling and cell proliferation in response to growth factors like EGF.

• It maintains expression of PP2A-C subunit, which reduces Raf-1 Ser-259 inhibitory phosphorylation .

• Silencing MST2 leads to increased Raf-1 Ser-259 phosphorylation and impaired MEK/ERK activation .

• This proliferative function can be rescued by expressing constitutively active MEK or Raf-1 mutants .

These opposing functions appear to depend on cellular context and the specific stimulus, making careful experimental design crucial for distinguishing between these roles .

What is the relationship between MST2 signaling and BRAF inhibitor resistance in melanoma?

MST2 plays a significant role in BRAF inhibitor resistance mechanisms:

• MST2-BRAF interaction:

  • Oncogenic BRAF V600E strongly interacts with MST2 and inhibits its pro-apoptotic signaling.

  • Wild-type BRAF shows only weak interaction with MST2 .

  • BRAF inhibitors (including PLX4032/vemurafenib) disrupt this interaction, releasing MST2 from inhibition .

• MST2 activation in BRAF-mutant cells:

  • BRAF inhibitor treatment causes rapid and sustained activation of MST1/2 in BRAF-mutant melanoma cells.

  • This activation contributes to the apoptotic response in BRAF inhibitor-sensitive cells .

  • Knocking down MST2 reduces BRAF inhibitor-induced apoptosis by 50-70% .

• MST2 pathway in resistance:

  • BRAF inhibitor-resistant melanoma cells show decreased expression of MST2 pathway components (MST2, LATS1, RASSF1A).

  • Both protein abundance and activation of MST2 pathway proteins are down-regulated during acquisition of resistance .

  • The mechanism involves increased ubiquitination and proteasomal degradation of MST2 and LATS1 .

This research suggests that maintaining MST2 pathway functionality could potentially enhance responses to BRAF inhibitor therapy .

How does MST2 regulate gene expression through microRNA-dependent mechanisms?

Recent research has uncovered an unexpected role for MST2 in microRNA-mediated gene regulation:

• MST-Dicer signaling axis:

  • MST positively regulates Dicer expression, establishing a novel MST-Dicer signaling pathway .

  • This pathway regulates both coding sequence (CDS) and untranslated region (UTR)-targeting miRNAs .

• WBP2 regulation:

  • MST blocks breast cancer by downregulating WBP2 through miRNA-dependent mechanisms.

  • MST regulates miR-23a expression, which directly targets the 3′UTR of WBP2 mRNA .

  • Significant inverse relationships exist between WBP2 and MST or miR-23a expression levels in clinical specimens .

• Mechanism complexity:

  • MST downregulates both exogenous WBP2 (without 3′UTR) and endogenous WBP2 (with 3′UTR).

  • This suggests involvement of both UTR-targeting and non-UTR-targeting miRNAs regulated by MST2 .

  • Endogenous WBP2 is downregulated to a greater extent by Dicer overexpression compared to miR-23a mimics alone .

This research identifies MST2 as a rheostat in the regulation of WBP2 and its oncogenic function, with implications for targeted therapeutics in breast cancer .

What are common challenges when working with MST2 antibodies and how can they be addressed?

Researchers may encounter several technical challenges when working with MST2 antibodies:

• Cross-reactivity concerns:

  • MST1 and MST2 share significant sequence homology, potentially leading to cross-reactivity.

  • Solution: Verify antibody specificity using knockout/knockdown controls or by comparing with antibodies targeting unique regions .

• Detection of activation state:

  • Distinguishing between inactive and active MST2 can be challenging.

  • Solution: Use phospho-specific antibodies (pT180) alongside total MST2 antibodies to assess activation ratio .

• Caspase-cleaved fragment detection:

  • The 36-kDa caspase-cleaved fragment may be difficult to detect.

  • Solution: Include caspase inhibitors (e.g., Z-VAD-FMK) in parallel samples to prevent complete degradation and improve detection .

• Optimizing immunoprecipitation:

  • IP efficiency can vary considerably between antibodies.

  • Solution: Test different antibody:lysate ratios (starting with recommended 1:25 dilution) and optimize binding conditions .

• Protein complex preservation:

  • MST2 interactions with binding partners may be disrupted during lysis.

  • Solution: Use mild lysis conditions and consider crosslinking approaches for transient interactions .

How can researchers design experiments to distinguish between the dual functions of MST2?

Given MST2's context-dependent roles in both proliferation and apoptosis, experimental design is critical:

• Stimulus-specific responses:

  • Use distinct stimuli: Growth factors (EGF) for proliferative functions versus apoptotic stimuli (doxorubicin, staurosporine) for pro-apoptotic functions .

  • Monitor timing: Proliferative signaling tends to be rapid (minutes to hours) while apoptotic responses develop over longer periods (hours to days) .

• Pathway-specific readouts:

  • Proliferative pathway: Monitor Raf-1 Ser-259 and Ser-338 phosphorylation, MEK/ERK activation .

  • Apoptotic pathway: Assess MST2 Thr-180 phosphorylation, caspase cleavage, PARP cleavage .

• Genetic manipulation approaches:

  • Use epistasis studies: Express constitutively active downstream components (MEK-DD, Raf-22W) to rescue phenotypes .

  • Compare knockdown effects in different contexts: Silencing MST2 reduces apoptosis but also impairs growth factor signaling .

• Interaction partner analysis:

  • Examine BRAF/Raf-1 interactions for proliferative functions .

  • Monitor LATS1/YAP interactions for Hippo pathway/apoptotic functions .

• Subcellular localization:

  • Track MST2 localization, as nuclear translocation often correlates with pro-apoptotic functions while cytoplasmic retention may favor proliferative roles .

What considerations are important when comparing data across different MST2 antibodies and experimental systems?

When integrating MST2 research findings across different experimental systems:

• Antibody validation parameters:

  • Compare epitope regions: Different antibodies may recognize distinct domains or modified forms of MST2.

  • Review validation methods: Western blot validation alone may not predict performance in IHC or IP applications .

  • Consider clones: Monoclonal antibodies provide consistent epitope recognition but may be sensitive to conformational changes .

• Cell type considerations:

  • MST2 functions may vary between cell types due to different expression levels of interaction partners.

  • BRAF mutational status significantly impacts MST2 function and should be documented (BRAF V600E vs. wild-type vs. NRAS mutant cells) .

• Experimental readouts:

  • Ensure comparable activation measurements: Some studies use phospho-T180 as activation marker while others examine downstream substrate phosphorylation .

  • Compare similar endpoints: Proliferation measures (cell counting, EdU incorporation) and apoptosis assays (Annexin V, TUNEL) should be standardized.

• Reporting standards:

  • Document antibody catalog numbers, dilutions, incubation conditions, and detection methods.

  • Include positive controls (staurosporine treatment for MST2 activation) and negative controls (MST2 knockdown/knockout) .

  • Consider reproducibility across multiple antibodies when possible to confirm key findings.

How can MST2 pathway manipulation be leveraged for cancer therapeutic strategies?

The dual role of MST2 in cellular signaling presents unique therapeutic opportunities:

• Enhancing BRAF inhibitor sensitivity:

  • Targeting the proteasomal degradation of MST2 pathway components could potentially overcome resistance to BRAF inhibitors in melanoma.

  • Combining proteasome inhibitors with BRAF inhibitors might preserve MST2 pathway integrity and enhance apoptotic responses .

• MST2-BRAF interaction targeting:

  • Developing compounds that disrupt the MST2-BRAF V600E interaction could potentially enhance MST2's pro-apoptotic functions in BRAF-mutant cancers.

  • Different BRAF inhibitor types (Type I ½ vs Type II) have varying effects on this interaction, suggesting structure-based drug design possibilities .

• MicroRNA-based approaches:

  • The MST-Dicer-miRNA regulatory axis could be therapeutically exploited.

  • miR-23a mimics might be used to downregulate WBP2 in breast cancer contexts where MST function is compromised .

• Combination strategies:

  • Understanding the differential activation of MST2 by various stimuli could inform rational combination therapies.

  • For example, doxorubicin's apoptotic effects depend partly on MST2, suggesting potential synergies with MST2 pathway activators .

What remains poorly understood about MST2 function that requires new antibody-based approaches?

Despite significant progress, several aspects of MST2 biology remain unclear and could benefit from advanced antibody-based approaches:

• Post-translational modifications:

  • Beyond Thr-180 phosphorylation, other PTMs of MST2 remain poorly characterized.

  • Development of antibodies targeting specific MST2 modifications (phosphorylation, acetylation, methylation) could reveal new regulatory mechanisms.

• Protein complexes and interactome:

  • The complete set of MST2 interaction partners across different cellular contexts remains incompletely defined.

  • Proximity labeling approaches combined with MST2 antibodies could map context-specific interactomes.

• Activation mechanisms in vivo:

  • The physiological triggers for MST2 activation in different tissues remain poorly understood.

  • Phospho-specific antibodies for immunohistochemistry could reveal activation patterns in tissue contexts.

• Non-canonical functions:

  • Emerging roles beyond Hippo signaling and Raf-1 regulation need further clarification.

  • The unexpected role in miRNA regulation suggests other non-canonical functions may exist .

• Isoform-specific functions:

  • Potential MST2 splice variants and their specific functions remain poorly characterized.

  • Isoform-specific antibodies could help distinguish these variants and their roles.

How might single-cell analysis using MST2 antibodies advance our understanding of cell population heterogeneity?

Single-cell approaches using MST2 antibodies could reveal important insights about cellular heterogeneity:

• Resistance mechanism heterogeneity:

  • BRAF inhibitor resistance may develop heterogeneously within tumor cell populations.

  • Single-cell analysis of MST2 pathway components could identify resistant subpopulations before bulk resistance emerges .

• Cell fate decision mapping:

  • Given MST2's dual role in proliferation versus apoptosis, single-cell analysis might reveal how individual cells resolve these competing signals.

  • This could identify factors that determine whether a cell undergoes apoptosis or survives following treatment.

• Spatial context influence:

  • Multiplexed immunofluorescence using MST2 antibodies alongside microenvironment markers could reveal how spatial context influences MST2 signaling.

  • This may explain heterogeneous responses to therapies within the same tumor.

• Temporal dynamics:

  • Single-cell live imaging with fluorescently-tagged antibody fragments could track MST2 activation dynamics in real-time.

  • This might reveal oscillatory behaviors or threshold effects in MST2 signaling.

• Combinatorial marker patterns:

  • Multiparameter analysis combining MST2 pathway components with other signaling pathways could identify novel cellular states.

  • This may be particularly relevant in understanding therapy resistance mechanisms involving multiple pathway adaptations .